Ioannis I. Andreadis

Mr. Ioannis I. Andreadis

Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
DFDimitrios Fatouros
Dimitrios Fatouros
The technological revolution has physically affected all manufacturing domains, at the gateway of the fourth industrial revolution. Three-dimensional (3D) printing has already shown its potential in this new reality, exhibiting remarkable applications in the production of drug delivery systems. As part of this concept, personalization of the dosage form by means of individualized drug dose or improved formulation functionalities has concentrated global research efforts. Beyond the manufacturing level, significant parameters must be considered to promote the real-time manufacturing of pharmaceutical products in distributed areas. The majority of current research activities is focused on formulating 3D-printed drug delivery systems while showcasing different scenarios of installing 3D printers in patients’ houses, hospitals, and community pharmacies, as well as in pharmaceutical industries. Such research presents an array of parameters that must be considered to integrate 3D printing in a future healthcare system, with special focus on regulatory issues, drug shortages, quality assurance of the product, and acceptability of these scenarios by healthcare professionals and public parties. The objective of this review is to critically present the spectrum of possible scenarios of 3D printing implementation in future healthcare and to discuss the inevitable issues that must be addressed.

1 November 2020 in Carbohydrate Polymers
Verified
Journal Article
Closed access
Christina KaravasiliChristina Karavasili
Christina Karavasili
KTKonstantinos Tsongas
Konstantinos Tsongas
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
EAEleftherios G. Andriotis
Eleftherios G. Andriotis
EPEleni T. Papachristou
Eleni T. Papachristou
DFDimitrios G. Fatouros
Dimitrios G. Fatouros

28 July 2020 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
Christina KaravasiliChristina Karavasili
Christina Karavasili
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
MTMaria P. Tsantarliotou
Maria P. Tsantarliotou
ITIoannis A. Taitzoglou
Ioannis A. Taitzoglou
PCPaschalina Chatzopoulou
Paschalina Chatzopoulou
DFDimitrios G. Fatouros
Dimitrios G. Fatouros

1 June 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
EKEleni Kontogiannidou
Eleni Kontogiannidou
Christina KaravasiliChristina Karavasili
Christina Karavasili
MKMaria G. Kouskoura
Maria G. Kouskoura
MFMaria Filippousi
Maria Filippousi
GTGustaaf Van Tendeloo
Gustaaf Van Tendeloo
DFDimitrios G. Fatouros
Dimitrios G. Fatouros

8 December 2021 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
Christina KaravasiliChristina Karavasili
Christina Karavasili
ATAngelos Thomas
Angelos Thomas
AKAnastasia Komnenou
Anastasia Komnenou
MTManolis Tzimtzimis
Manolis Tzimtzimis
DFDimitrios Fatouros
Dimitrios Fatouros

24 April 2019 in Expert Review of Precision Medicine and Drug Development
Verified
Journal Article
Closed access
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
AMAndroulla N. Miliotou
Androulla N. Miliotou
Georgios MystridisGeorgios Mystridis
Georgios Mystridis
Eleftherios AndriotisEleftherios Andriotis
Eleftherios Andriotis
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
DFDimitrios G. Fatouros
Dimitrios G. Fatouros
Introduction: Nowadays, nanotechnology and genomics contribute knowledge and innovative practices, enabling pharmacological interventions as well as theraputic decisions to be applicable on a personal basis, i.e., establishing precision (personalized) medicine approaches into the clinical setting. However, the dynamics and the evolution capacity of organisms over time necessitate the advancement of powerful interdisciplinary tools, population-based pharmacological methodologies, as well as the application of translational methodologies with clinical implementation capabilities. Areas covered: Even for newly emerged techniques, like three-dimensional (3D) bioprinting nanoplatforms and in vitro transcribed (IVT)-mRNA therapeutics, the patients’ heterogeneity still hinders their potential exploitation in a broader perspective and clinical outcome burden. It is thus essential that the recently developed computational physiologically-based pharmacokinetic (PBPK) models present tools aiming to predict differential pharmacological response in patient groups and to allow cost-effective individualized dosage adjustments for populations worldwide. Expert opinion: The recent advancements in IVT-mRNA therapeutics and 3D bioprinting technologies, along with the capabilities of PBPK modeling to delineate the issue of interpatient heterogeneity, will be presented and discussed. Also, the integration of core interdisciplinary infrastructures will be included in a manner to better serve the task of more efficiently and productively achieving precision medicine interventions in the everyday clinical practice.